These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24789783)

  • 1. Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D.
    Whitbeck JC; Huang ZY; Cairns TM; Gallagher JR; Lou H; Ponce-de-Leon M; Belshe RB; Eisenberg RJ; Cohen GH
    J Virol; 2014 Jul; 88(14):7786-95. PubMed ID: 24789783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
    Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
    PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
    Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
    J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.
    Cairns TM; Huang ZY; Whitbeck JC; Ponce de Leon M; Lou H; Wald A; Krummenacher C; Eisenberg RJ; Cohen GH
    J Virol; 2014 Nov; 88(21):12612-22. PubMed ID: 25142599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging.
    Cairns TM; Ditto NT; Lou H; Brooks BD; Atanasiu D; Eisenberg RJ; Cohen GH
    PLoS Pathog; 2017 Jun; 13(6):e1006430. PubMed ID: 28614387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
    Awasthi S; Belshe RB; Friedman HM
    J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
    Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
    J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.
    Awasthi S; Hook LM; Swaminathan G; Cairns TM; Brooks B; Smith JS; Ditto NT; Gindy ME; Bett AJ; Espeseth AS; Cohen GH; Friedman HM
    Vaccine; 2019 Jun; 37(29):3770-3778. PubMed ID: 31153687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
    ; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
    Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
    Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and evaluation of a multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infection in BALB/c mice.
    Wang X; Xie G; Liao J; Yin D; Guan W; Pan M; Li J; Li Y
    Virol J; 2011 May; 8():232. PubMed ID: 21575169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy.
    Liu K; Jiang D; Zhang L; Yao Z; Chen Z; Yu S; Wang X
    Vaccine; 2012 Apr; 30(19):3034-41. PubMed ID: 22008818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to Crucial Epitopes on HSV-2 Glycoprotein D as a Guide to Dosing an mRNA Genital Herpes Vaccine.
    Hook LM; Awasthi S; Cairns TM; Alameh MG; Fowler BT; Egan KP; Sung MMH; Weissman D; Cohen GH; Friedman HM
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.
    Wang K; Dropulic L; Bozekowski J; Pietz HL; Jegaskanda S; Dowdell K; Vogel JS; Garabedian D; Oestreich M; Nguyen H; Ali MA; Lumbard K; Hunsberger S; Reifert J; Haynes WA; Sawyer JR; Shon JC; Daugherty PS; Cohen JI
    J Infect Dis; 2021 Nov; 224(9):1509-1519. PubMed ID: 33718970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.